Zacks Investment Research upgraded shares of UNILIFE CORP (UNIS) from NEUTRAL to OUTPERFORM on January 15, 2013, with a target price of $2.60.
Unilife Corporation is a medical device company based in U.S., focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. The primary target customers for the Company's products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife's main product is the Unifill ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with injectable drugs and vaccines. Unilife Corporation has FDA-registered medical device manufacturing facilities in Pennsylvania.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on UNILIFE CORP (UNIS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment